I Drove My Inflammation Number to Almost Zero. A Big Trial Says That Wasn’t What Mattered.
Updated September 7, 2026 with the HERMES and ATHENA trials both stopped early. ZEUS lowered inflammation exactly as designed and did not cut cardiovascular events. That weakens hs-CRP as something to treat, not as something worth measuring. Update, August 22, 2026: the people behind the colchicine trials have answered ZEUS, and a new UK Biobank










